Pharma Focus Asia
KP - Choose our fully recyclable blister films

Heptares Therapeutics and Kymab Limited to Develop Novel Antibody Therapeutics

Heptares Therapeutics (also known as Heptares) and Kymab Limited have entered into a strategic collaboration to discover, develop and commercialise novel antibody therapeutics.

New therapeutics will target a number of G protein-coupled receptors (GCPRs) with an initial focus on immune-oncology (a new area in the treatment of cancer).

GPCRs are generally expressed on cells of the innate and adaptive immune system. They play a major role in modulating cell migration & recruitment to the tumour environment, activation, survival, production and delineation. They can be targeted by novel immunotherapy antibodies.

To create secure antigens based on various GPCR targets, Heptares will apply its StaR® platform. Kymab will then utilise its Kymouse™ human antibody discovery platform to produce antibodies in response to immunisation with these antigens.

On the other hand, the Kymouse platform provides the possibility of finding the best-in-class antibodies with superior drug properties.

Promising leads will be progressed using the partners' corresponding skills, resources and development capabilities to bring pioneering products into the clinic.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024